News

Three patients enrolled in the second dose level cohort completed the first treatment cycle and well tolerated the L-DOS47 therapy. Patients to be enrolled in the third cohort

The oral drug candidate APD334 is formulated to target the sphingosine 1-phosphate subtype 1 (S1P1) receptor believed to take part in the modulation of various biological responses. Arena

Livalo, developed by Kowa, is a cholesterol-lowering agent and Olmetec, developed by Daiichi, is an antihypertensive agent. Both the companies have been jointly marketing the drugs in the

The supercomputer and its supporting e-infrastructure will help over 500 life sciences and biomedical researchers, physicians and students from a consortium to gain further insights into chronic diseases

Oncomine Gene Browser will allow cancer researchers to search premier cancer genomics database for expression, copy number and mutation data while Ion Reporter Oncomine Workflow is an end-to-end

Under the partnership, Horizon will share its X-Gene Mutant and Normal (X-MAN ) cell lines with Crown who will provide animal model development, study execution and business marketing

All the capital stock of Althea is purchased by Ajinomoto at closing for approximately $175m. Althea will turn out to be a fully consolidated subsidiary of Ajinomoto, doing

GenePrint10 consists of the eight loci recommended by the ANSI Standard (ASN-0002) Authentication of Human Cell Lines: Standardization of STR Profiling, plus Amelogenin for gender identification and the

The patent describes the format and methodology of T2Candida test, desinged to detect and identify Candida species in a blood sample. T2Candida will identify sepsis-causing Candida species directly